MA34516B1 - Imidizopyridazines substituees - Google Patents

Imidizopyridazines substituees

Info

Publication number
MA34516B1
MA34516B1 MA35720A MA35720A MA34516B1 MA 34516 B1 MA34516 B1 MA 34516B1 MA 35720 A MA35720 A MA 35720A MA 35720 A MA35720 A MA 35720A MA 34516 B1 MA34516 B1 MA 34516B1
Authority
MA
Morocco
Prior art keywords
compounds
imidizopyridazines
substituted
formula
ttk
Prior art date
Application number
MA35720A
Other languages
English (en)
Inventor
Ulrich Klar
Marcus Koppitz
Rolf Jautelat
Dirk Kosemund
Rolf Bohlmann
Philip Lienau
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34516B1 publication Critical patent/MA34516B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paper (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

)CETTE INVENTION CONCERNE DES COMPOSÉS D'IMIDAZOPYRIDAZINES SUBSTITUÉES DE FORMULE GÉNÉRALE (1), QUI SONT DES INHIBITEURS DE MPS-1 (FUSEAU MONOPOLAIRE 1) (ÉGALEMENT CONNU SOUS LE NOM DE TYROSINE THRÉONINE KINASE, TTK), R3, R5, ET A DANS LA FORMULE (1) ÉTANT TELS QUE DÉFINIS DANS LES REVENDICATIONS, AINSI QUE DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET L'UTILISATION DESDITS COMPOSÉS POUR FABRIQUER UNE COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR UNE MALADIE, EN PARTICULIER, UN TROUBLE HYPER-PROLIFÉRATIF ET/OU DE TYPE ANGIOGENÈSE, À TITRE D'AGENT UTILISÉ SEUL OU EN ASSOCIATION AVEC D'AUTRES PRINCIPES ACTIFS.
MA35720A 2010-09-10 2011-09-06 Imidizopyridazines substituees MA34516B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP11075022 2011-02-04
EP11170771 2011-06-21
EP11170775 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (fr) 2010-09-10 2011-09-06 Imidazopyridazines substituées

Publications (1)

Publication Number Publication Date
MA34516B1 true MA34516B1 (fr) 2013-09-02

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35720A MA34516B1 (fr) 2010-09-10 2011-09-06 Imidizopyridazines substituees

Country Status (38)

Country Link
US (1) US9255100B2 (fr)
EP (1) EP2614063B1 (fr)
JP (1) JP5824050B2 (fr)
KR (1) KR20140032337A (fr)
CN (1) CN103370318B (fr)
AP (1) AP3607A (fr)
AR (1) AR082946A1 (fr)
AU (1) AU2011298844B2 (fr)
BR (1) BR112013005679A2 (fr)
CA (1) CA2810755A1 (fr)
CO (1) CO6720961A2 (fr)
CR (1) CR20130102A (fr)
CU (1) CU24187B1 (fr)
CY (1) CY1117352T1 (fr)
DK (1) DK2614063T3 (fr)
DO (1) DOP2013000054A (fr)
EA (1) EA023420B1 (fr)
EC (1) ECSP13012752A (fr)
ES (1) ES2568220T3 (fr)
HK (1) HK1187623A1 (fr)
HR (1) HRP20160360T1 (fr)
HU (1) HUE028771T2 (fr)
IL (1) IL225058A (fr)
MA (1) MA34516B1 (fr)
ME (1) ME02389B (fr)
MX (1) MX2013002713A (fr)
MY (1) MY185139A (fr)
NZ (1) NZ607904A (fr)
PE (1) PE20131164A1 (fr)
PL (1) PL2614063T3 (fr)
RS (1) RS54661B1 (fr)
SA (1) SA111320735B1 (fr)
SG (1) SG188417A1 (fr)
SI (1) SI2614063T1 (fr)
TW (1) TWI541243B (fr)
UY (1) UY33598A (fr)
WO (1) WO2012032031A1 (fr)
ZA (1) ZA201301756B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
CN104284896B (zh) * 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014075168A1 (fr) * 2012-11-16 2014-05-22 University Health Network Composés de pyrazolopyrimidine
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
AP2015008898A0 (en) 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
CN105392484A (zh) * 2013-06-13 2016-03-09 拜耳制药股份公司 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3107909B1 (fr) * 2014-02-21 2021-07-14 Frost Biologic, Inc. Amides antimitotiques destinés au traitement du cancer et de troubles prolifératifs
WO2015157955A1 (fr) * 2014-04-17 2015-10-22 Abbvie Inc. Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PL3283642T3 (pl) 2015-04-17 2024-04-22 Crossfire Oncology Holding B.V. Biomarkery prognostyczne dla chemioterapii inhibitorem TTK
WO2016187028A1 (fr) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Composés hétéroaryles, leur synthèse, et intermédiaires de ceux-ci
CN108290749B (zh) * 2015-12-04 2022-06-24 埃克森美孚科技工程公司 Emm-28新型合成结晶材料、其制备和用途
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
JP6961675B2 (ja) * 2016-07-18 2021-11-05 ユニバーシティー ヘルス ネットワーク Ｔｔｋ阻害剤の固体形態
US20200078142A1 (en) * 2017-04-11 2020-03-12 Straumann Holding Ag Dental implant
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2019213506A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Sels d'un inhibiteur de fgfr
CA3127502A1 (fr) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CA3162010A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Derives d'un inhibiteur de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
CA3241213A1 (fr) * 2021-12-15 2023-06-22 Heidi Lane Combinaisons pharmaceutiques destinees a etre utilisees dans le traitement du cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
EP1713784A1 (fr) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines et ligands associes des recepteurs de benzodiazepine
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AR056785A1 (es) * 2005-11-10 2007-10-24 Schering Corp COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
JP2010524953A (ja) * 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
EP2217601A1 (fr) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (fr) 2009-01-31 2010-08-05 Kalypsys, Inc. Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
CN102413831B (zh) * 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (fr) 2009-09-04 2017-06-27 Benjamin Bader Aminoquinoxalines substituees servant d'inhibiteurs de tyrosine-threonine kinases
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103403006B (zh) 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
EP2651950A1 (fr) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines 6-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
CA2821837A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines 2-substituees pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation
ES2556458T3 (es) 2010-12-17 2016-01-18 Bayer Intellectual Property Gmbh 6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
EP2651945A1 (fr) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines 6-substituées pour utilisation en tant qu'inhibiteurs de mps-1 et tkk dans le traitement de troubles hyperprolifératifs
CA2821829A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation

Also Published As

Publication number Publication date
CR20130102A (es) 2013-04-17
SG188417A1 (en) 2013-04-30
CU24187B1 (es) 2016-07-29
DOP2013000054A (es) 2013-07-31
JP5824050B2 (ja) 2015-11-25
AU2011298844A1 (en) 2013-03-28
BR112013005679A2 (pt) 2016-05-03
PE20131164A1 (es) 2013-10-30
SI2614063T1 (sl) 2016-05-31
IL225058A (en) 2017-03-30
PL2614063T3 (pl) 2016-06-30
ECSP13012752A (es) 2014-01-31
ME02389B (fr) 2016-09-20
ZA201301756B (en) 2016-06-29
CY1117352T1 (el) 2017-04-26
AP3607A (en) 2016-02-26
JP2013537174A (ja) 2013-09-30
KR20140032337A (ko) 2014-03-14
TWI541243B (zh) 2016-07-11
DK2614063T3 (en) 2016-04-18
MY185139A (en) 2021-04-30
EP2614063A1 (fr) 2013-07-17
HK1187623A1 (zh) 2014-04-11
EA201390339A1 (ru) 2013-09-30
SA111320735B1 (ar) 2015-10-21
HRP20160360T1 (hr) 2016-05-06
CN103370318B (zh) 2016-04-20
CA2810755A1 (fr) 2012-03-15
CU20130033A7 (es) 2013-08-29
ES2568220T3 (es) 2016-04-28
AR082946A1 (es) 2013-01-23
CO6720961A2 (es) 2013-07-31
CN103370318A (zh) 2013-10-23
EP2614063B1 (fr) 2016-01-13
TW201211049A (en) 2012-03-16
RS54661B1 (en) 2016-08-31
US9255100B2 (en) 2016-02-09
MX2013002713A (es) 2013-05-22
US20130338133A1 (en) 2013-12-19
WO2012032031A1 (fr) 2012-03-15
HUE028771T2 (en) 2016-12-28
AU2011298844B2 (en) 2015-02-19
EA023420B1 (ru) 2016-06-30
NZ607904A (en) 2015-02-27
UY33598A (es) 2012-04-30
AP2013006790A0 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
MA34516B1 (fr) Imidizopyridazines substituees
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA41179A (fr) Composés inhibiteurs de parg
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
TNSN08139A1 (fr) Composes therapeutiques
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA34308B1 (fr) Triazolopyridines substituées
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30655B1 (fr) Composes organiques.
MA35187B1 (fr) Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
MA38391B1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA41434B1 (fr) 7-benzyl-4-(4-(trifluorométhyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one, ses sels et leur utilisation en thérapie
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1